STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNF? mediated immune responses in a model of NSCLC.

ABSTRACT: In this study we described that Signal Transducer and Activator of Transcription 1 (STAT1) is a key point regulator of PD-1 in tumour infiltrating lymphocytes and PD-L1 in Tumour associated macrophages (TAM) in NSCLC. In our murine model of adenocarcinoma targeted deletion of Stat1 was found associated with enhanced tumour growth, impaired differentiation into M1-like macrophages from the bone marrow, the accumulation of tumor associated macrophages overexpressing PD-L1 and impaired T cell responses in the tumor microenvironment by affecting TNF? responses. In our human NSCLC patient cohort we found that loss of isoforms STAT1 ? and STAT1? mRNA in the tumoural region of the lung correlates with increased tumor size in NSCLC patients. Therefore, STAT1 isoform regulation could be considered for future therapeutical strategies associated to current immune-checkpoint blockade therapy in NSCLC.

SUBMITTER: Friedrich J 

PROVIDER: S-EPMC6324686 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature